New Phase 3 Data at WCPGHAN Show Long-Term Safety, Tolerability, and Treatment Benefits of Bylvay™ (odevixibat) in PFIC

NEXT STORY
Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
PREV STORY
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Worldwide Endocrine Testing Market 2018-2023 – Hoffmann-La Roche, Thermo Fisher Scientific and Abbott are Key Players

author_avatar
NASDAQ Market News

Albireo Provides First Quarter 2018 Business Update

 First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFIC   Elobixibat ...

author_avatar
NASDAQ Market News

XBiotech Announces European Medicines Agency (EMA) Validates Marketing Authorization Application (MAA) for Xilonix™ in the Treatment of Advanced Colorectal Cancer

AUSTIN, Texas, March 23, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that ...

author_avatar
NASDAQ Market News